The American Diabetes Association's 74th Scientific Sessions, billed as "the world's foremost meeting on diabetes," will feature more than 14,000 top scientists, physicians, and other health care professionals sharing "cutting-edge research, treatment recommendations and advances toward a cure for diabetes."
Combination Treatment with SGLT2 Inhibitor Dapagliflozin Is Effective in Patients with Type 2 Diabetes
Evaluating the Long-term Efficacy and Safety of SGLT2 Inhibitor Canagliflozin in Older Patients with Type 2 Diabetes
Empagliflozin Monotherapy Trial Extension Highlights Advantages of SGLT2 Inhibitors for Treatment of Type 2 Diabetes
Novel, Incretin-based Oral Combination Therapy: A Possible Replacement for Insulin as First-line Therapy in Newly Diagnosed Type 2 Diabetes Patients
Do Incretin-based Therapies Increase the Risk of Developing Acute Pancreatitis in Patients with Diabetes?
Efficacy and Safety of IDegLira in Patients with Type 2 Diabetes Maintained After 1 Year of Treatment